Last reviewed · How we verify
Cirmtuzumab plus ibrutinib
At a glance
| Generic name | Cirmtuzumab plus ibrutinib |
|---|---|
| Also known as | UC-961, Imbruvica |
| Sponsor | Oncternal Therapeutics, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (PHASE1, PHASE2)
- A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cirmtuzumab plus ibrutinib CI brief — competitive landscape report
- Cirmtuzumab plus ibrutinib updates RSS · CI watch RSS
- Oncternal Therapeutics, Inc portfolio CI